TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
Betsy Goodfellow | April 10, 2024 | News story | Research and Development | Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer.
The results were announced at the American Association for Cancer Research (AACR) Annual Meeting 2024.
The trial has demonstrated that TILT-123 in combination with Merck’s (known as MSD outside of the US and Canada) Keytruda (pembrolizumab) was safe and showed signs of efficacy in both platinum resistant and refractory ovarian cancer patients. According to the company’s press release, ‘analysis of biological samples revealed insights into mechanism of action, including an immunological profile potentially predictive of clinical response’.
The study included 15 patients who were given either intratumoural or intraperitoneal doses of the drug in combination with intravenous doses of Keytruda. Disease control was demonstrated in 71% of evaluable patients as well as one long lasting parial response in a patient with mucinous carcinoma. Reductions in tumour size and significant immunomodulation were seen in both injected and non-injected tumours.
Akseli Hemminki, TILT Biotherapeutics’ chief executive officer and founder, commented: “We are excited to see the latest ongoing positive potential to bring a more effective treatment to patients with refractory ovarian cancer that have few other treatment options. Importantly, an immune response and reduction in tumour size was seen from intratumoural injections of the combination therapy as well as those away from the tumour site, which demonstrates the potential for a systemic response.”
Betsy Goodfellow
Related Content
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint
Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
